Evidence map›Paper›PMID 42064808›Full record

ReviewFrontiers in pharmacology2026

Nanotechnology-based drug formulation and delivery systems for skin medical aesthetic dermatology: mechanisms, applications, and safety.

Luqi Wang, Debao Yu

Abstract readReview
In one paragraph

Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Luqi WangDepartment of Medical Aesthetics, Jinan Institute of Dermatology Prevention and Treatment Jinan, Shangdong, China.
Debao YuDepartment of Medical Aesthetics, Jinan Institute of Dermatology Prevention and Treatment Jinan, Shangdong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Medical aesthetic dermatology is expanding rapidly in response to increasing demand for minimally invasive interventions and advanced topical therapies. The clinical performance of conventional dermatological formulations is frequently limited by inadequate skin penetration, poor stability of active ingredients, rapid degradation, and dose-related adverse effects. Nanotechnology-based drug formulation and delivery systems offer a translational solution to these challenges by enabling targeted, controlled, and sustained delivery of bioactive compounds to specific skin layers and appendages. Nanoscale carriers-including lipid-based systems, polymeric nanoparticles, nanoemulsions, and inorganic or hybrid nanomaterials-enhance dermal and follicular deposition, improve physicochemical stability, and modulate release kinetics of therapeutic and cosmeceutical agents. These mechanisms have facilitated improved outcomes across key aesthetic indications, including skin rejuvenation, pigmentary disorders, acne, hair restoration, and injectable aesthetic interventions. Emerging clinical and preclinical evidence suggests improved local efficacy and potentially reduced irritation and systemic exposure compared with conventional formulations, although further well-controlled clinical studies are required to confirm these benefits. Safety, toxicological behavior, and regulatory considerations remain critical determinants of successful clinical translation, particularly with respect to long-term exposure and nanoparticle-skin interactions. Integration of pharmacological mechanisms with clinical performance highlights the growing role of nanotechnology in redefining therapeutic strategies within medical aesthetic dermatology and supports its continued development within evidence-based translational pharmacology frameworks.

Indexed as

aesthetic dermatologydermaldrug deliverynanocarriersnanotechnologyskin penetrationtranslational pharmacology

Identifiers

PMID42064808
PMCPMC13125078

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.